Abstract: The present invention relates to a compound having a structure in which isotretinoin is linked to a peptide via a covalent bond and an antibiotic, anti-inflammatory, or anti-oxidative pharmaceutical or cosmetic composition comprising the same. A compound having a structure in which isotretinoin is linked to a peptide via a covalent bond according to the present invention exhibits excellent physiological activity such as antibiotic, anti-inflammatory, or anti-oxidative actions, as well as having outstanding properties, such as solubility in water, etc., and thus can find useful applications in various fields including medicines, cosmetics, etc.

Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

Abstract: The present invention relates generally to glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a spacer containing ((2-oxoethyl)thio)). In an aspect the invention provides oxo-eT linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a ((2-oxoethyl)thio) spacer having the formula (I): wherein: A is a group (C?X)m wherein X is S or O and m is 0 or 1; B is a bond, O, or CH2; and when m is 0, B can also be (C?O); R is a C2-C16 alkylene, C2-C16 heteroakylene, NH—C(?O)—C2-C16 alkylene, or NH—C(?O)—C2-C16 heteroakylene, wherein said alkylene and heteroalkylene are optionally substituted by 1, 2 or 3 groups independently selected from COOR? where R? is selected from H, methyl, ethyl or propyl. The invention further relates to immunogenic compositions comprising such glycoconjugates, and to methods for the preparation and use of such glycoconjugates and immunogenic compositions.

Abstract: The present disclosure is directed at an antibody conjugate having an antibody and a tag, wherein one or more element(s) present in the antibody exhibit an isotope ratio which differs from the naturally occurring isotope ratio of the one or more element(s), wherein the amount of the isotope which is less-common in nature, is increased to at least 4% of the atoms of the respective element in the antibody, as well as uses thereof.

Abstract: Disclosed herein are surfactant free lyophilized formulations of antibody-drug conjugates (ADCs), such as anti-tissue factor ADCs, and reconstituted formulations, processes and uses thereof. The formulations are particularly suitable for an anti-TF ADC based on an auristatin derivative or other similarly hydrophobic drug. Typically, the excipients of the formulations comprise or consist of histidine, sucrose, trehalose, mannitol and glycine.

Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.

Abstract: Provided are novel anti-CD228 antibodies and antibody-drug conjugates and methods of using such anti-CD228 antibodies and antibody-drug conjugates to treat cancer.

Abstract: The present disclosure provides anti-CD22 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.

Abstract: Anticancer virus particles are described. Anticancer virus particles are filamentous or rod-shaped plant virus particle containing an anticancer agent within the interior of the virus particle. The anticancer agent can be attached either covalently or non-covalently within the interior of the virus particle. A therapeutically effective amount of an anticancer virus particle can be administered to a subject identified as having cancer to provide a method of cancer treatment.

Abstract: Targeted drug delivery systems comprising a therapeutic agent solubilized with undecylenic acid (UA)-based nanocarrier vesicles that may be polymerized or provided as an mPEG ester are provided to achieve targeted delivery of, for example, ROS-activated cytotoxic agents to cancer cells exhibiting high levels of ROS. Methods utilizing photodynamic and sonodynamic generation of ROS to enhance targeted delivery are also provided.

Abstract: The present disclosure provides compositions and methods directed to the synthesis and use of SNAs with a sheddable PEG layer that incorporates an enzyme-sensitive linker.

Abstract: A method of generating a soluble dihydromyricetin formulation may involve generating an acidic solution with a pH ranging between 2-7 pH in a reaction vessel by combining an organic acid in an aqueous solution at a first temperature range. The method may then generate a solvent mixture by combining the acidic solution with a sugar. The method may then heat the solvent mixture to a boil and then adjust the heat to the first temperature range generating a heated solvent mixture. The method may then combine cyclodextrin and dihydromyricetin (DHM) with the heated solvent mixture forming a DHM solution. The method may then mix the DHM solution at a first speed for a first time interval in a mixer. The method may then heat a mixed DHM solution at a second temperature range for a second time interval.

Abstract: Described herein are methods and compositions for treating MPS I (Hurler) disease.

Abstract: Non-viral nucleic acid delivery agents and methods for the delivery or transfer of nucleic acid molecules to target cells are disclosed. The agents comprise a complex of a nucleic acid cargo for delivery, one or more lipopeptide compound, and one or more polymeric charge-neutralising agent, and the complex is in the form of a particle with substantially neutral or negative surface charge. The agents and methods may be useful in a variety of applications such as therapies (including gene therapies and nucleic acid vaccinations) for diseases and medical disorders.

Abstract: Embodiments disclosed herein provide methods for modulating intestinal epithelial cell integrity, migration, proliferation, differentiation, maintenance and/or function in which the expression of Cp1orf106 or its protein product are modulated such that the stability of the protein is altered. In certain example embodiments, increasing the stability or preventing a decrease in the stability of Cp1orf106 protein increases the overall integrity of the intestinal epithelium, thereby resulting in a decreased incidence of inflammatory disease. Increased integrity or stability of the epithelium may prevent invasion of migratory cells such as cancer cells.

Abstract: Methods of the present invention predict a physiological state of a subject. A composition comprising activity sensors is introduced into a body of a subject. The activity sensors comprise a plurality of reporters susceptible to cleavage when processed by the body during extracellular matrix remodeling. Cleavage may be indicative of enzymatic activity in the extracellular matrix. Signals detected by the activity sensors may be predictive of a physiological state. A sample is collected from the subject, and liberated reporters are detected in the sample. An onset of the physiological state of the subject, which may be a disease characterized by inflammation or atrophy, may be diagnosed based on the liberated reporters detected.

Abstract: The present provides a Positional Isotopomer NMR Tracer Analysis (PINTA) method that can be used to noninvasively assess rates of hepatic mitochondrial oxidation (VCS) and/or pyruvate carboxylase (VPC) flux in a subject. In certain embodiments, the methods utilize a combined NMR/gas chromatography-mass spectrometry analysis of plasma following infusion of [3-13C]lactate and glucose tracer. The method of the invention provides investigators with a tool to non-invasively examine the role of altered hepatic mitochondrial metabolism and study the effects of therapeutic interventions for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and type 2 diabetes (T2D).

Abstract: There is described a method for the preparation of a hyperpolarised target molecule, wherein said molecule comprises at least one —OH, —NH or —SH moiety, via proton exchange from a polarisable molecule, said method comprising the steps of: (i) preparing a fluid containing a transfer catalyst; parahydrogen; and a polarisable molecule containing at least one exchangeable proton, such as, an —OH, —NH or —SH moiety; (ii) applying a magnetic field or radio frequency excitation such that hyperpolarisation is transferred from parahydrogen to the polarisable molecule when bound to the magnetisation transfer catalyst; (iii) separately or simultaneously introducing a target molecule, wherein said target molecule contains at least one —OH, —NH or —SH exchangeable proton, enabling hyperpolarisation transfer via proton exchange with the polarisable molecule.

Abstract: The present invention provides methods of using nitroxide spin-labeled amyloid beta-binding compounds to image amyloid. The present invention also provides nitroxide spin-labeled amyloid beta-binding compounds.

Abstract: Disclosed is a method of preparing a drug-iodinated oil dispersion by high-pressure dissolution. In the invention, drug molecules are dissolved in and thoroughly mixed with iodinated oil under high pressure and rapid stirring. After the depressurization, the drug molecules are dispersed in the iodinated oil to prepare a uniformly-mixed drug-iodinated oil dispersion. The drug-iodinated oil dispersion prepared herein, compared to the drug-iodinated oil suspension and emulsion, has advantages of controllable morphology, long-term stability and slow drug-releasing rate, moreover, the drug molecules do not negatively affect the iodinated oil in physicochemical properties such as viscosity. In the liver cancer treatment, the prepared drug-iodinated oil dispersion is firstly injected through the hepatic arteries to perform the embolization, and the drug molecules are slowly released for a sustained treatment. The invention provides a good reference for the therapy combined with iodinated oil embolization.

Abstract: Lu-containing compositions comprising a particle coated by a Lu-containing film are disclosed. The process of depositing the Lu-containing film on the particle is also disclosed.

Abstract: A method and apparatus for pasteurizing and drying cannabis plant materials using a microwave-vacuum chamber. The pasteurizing and drying are carried out with no use of ionizing radiation and with rapid drying. Pasteurization is done at a temperature and for a time period that are sufficient to reduce microorganisms to an acceptably low level, while not significantly reducing the psychoactive compounds in the material. In the process, the pressure inside a vacuum chamber is reduced to a first pressure less than atmospheric. The material is maintained in the vacuum chamber at the first pressure at a pasteurizing temperature while irradiating the material with microwave radiation. The pressure is then reduced to a second pressure lower than the first pressure and the material is maintained in the vacuum chamber at the second pressure for a time period at a dehydrating temperature lower than the pasteurizing temperature while irradiating the material with microwave radiation.

Abstract: Disclosed herein are flexible plasma applicators based on fibrous layers that are capable of rapidly sanitizing a surface via either direct or indirect contact with said surface.

Abstract: A lubricant for a medical device to be subjected to gas low temperature sterilization includes an anti-friction material and an ion exchanger.

Abstract: The present disclosure generally relates to an ozone sanitizing system and method. In one embodiment, a system for sanitizing various objects using ozone gas is disclosed. The system comprises an ozone generating device configured generate ozone gas for sanitizing one or more objects, and a vessel configured to couple with the ozone generating device for receiving the ozone gas to sanitize the one or more objects stored inside the vessel during an ozone sanitizing cycle. The system is configured to recirculate at least a gas mixture generated during the ozone sanitizing cycle to increase an ozone concentration inside the vessel.

Abstract: The invention relates to a pasty preparation for forming a semirigid dressing, said preparation having the following formulation: 30-70% by weight water, 1-10% by weight gelling agent, 10-40% by weight glycerol or polyvalent alcohols, in particular propylene glycol or sorbitol, 0-30% by weight oil, 0.5-5% by weight water-soluble salts, 0.5-2% by weight rheological fillers, and 1-5% adsorbent fillers.

Abstract: A disposable moisture detection component manufactured from a water soluble conductive polymer film-forming and printable mixture with a resistivity of 100 ohms or less. Moisture detection component is embedded in incontinent articles such as diapers and bedpans. Conductive polymer dissolves in the presences of urine or feces and when connected to an electronic circuit, provides diaper status to a caregiver.

Abstract: Liquid embolic preparations and medical treatment methods of using those preparations are described. In some embodiments, the preparations or solutions can transition from a liquid to a solid for use in the embolization. The preparations can include biocompatible polymers with covalently bound radioactive iodine isotopes.

Abstract: Provided herein is a class of reversible thermal gel polymers, formulations thereof, methods for using, and methods for making said reversible thermal gel polymers. Reversible thermal gel polymers and formulations are provided having versatile chemical, physical, mechanical and/or optical properties beneficial for a range of applications including medical treatment. In some embodiments, the architecture and composition of the polymer allows for tunable selection of one or more physical properties supporting a particular application.

Abstract: Described herein are compositions comprising at least two diblock copolypeptides, wherein each copolypeptide has an ionic segment with the opposite charge from the other. The copolypeptides form ?-sheet structured hydrogel assemblies via polyion complexation when mixed in aqueous media. As a result of their unique physical properties, the hydrogels are useful as cell suspension or cell culture media, in drug or cell delivery systems, in scaffolds for tissue repair, or as 3d-printable media.

Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

Abstract: A biopolymer fiber containing collagen. The biopolymer fiber has excellent ultimate tensile strength, modulus of elasticity, and strain at break comparable to native human tendons and ligaments. The fiber may substantially circular, ovoid, square, rectangular, ribbon-like, triangular, or irregularly shaped. The fiber exhibits an ordered, longitudinally-oriented structure, and the fiber allows infiltration of cellular growth. Implantable biopolymer scaffolds and sutures containing the fibers are provided as well as microfluidic and extrusion methods for producing the biopolymer fibers.

Abstract: The present disclosure provides meshed acellular dermal tissue matrix compositions, devices, and methods of use. The meshed devices can be used in conjunction with a variety of implants such as breast implants or tissue expanders.

Abstract: The invention relates to methods of preparing matrices, and compositions therefor. In particular, the invention relates to methods of preparing collagen matrices, and compositions therefor, including kits and graft compositions.

Abstract: Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.

Abstract: Provided is an implant configured to fit at or near a bone defect to promote bone growth, the implant comprising: a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and an oxysterol in an amount of about 20 wt % to about 90 wt % of the implant. The implant has a high oxysterol load. Methods of making and use are further provided.

Abstract: A resin composition for a medical device to be subjected to gas low-temperature sterilization includes a resin and an ion exchanger.

Abstract: Articles for reducing the risk of infection, bearing, or containing an antimicrobial composition containing a solid-phase peroxyxcarboxylic acid metal salt are provided. Methods of reducing the risk of infection using the antimicrobial composition are also provided.

Abstract: An antimicrobial article, a cell culture article, an antithrombotic article, or a biopharmaceutical article that can reduce adhesion of proteins, blood components, cells, or bacteria containing a copolymer that contains a polymerized unit (A) represented by —CH2—CHOH— and a polymerized unit (B) represented by —CH2—CX2—, wherein Xs are the same as or different from each other, and are each an alkyl group having a linear, branched, or cyclic structure, and optionally containing an oxygen atom between carbon atoms, an alkoxy group having a linear, branched, or cyclic structure, and optionally containing a hetero atom between carbon atoms, a siloxy group having a carbon number of 3 or greater, an ester group containing an aromatic ring or an alkyl group and having a linear, branched, or cyclic structure, or H, excluding those in which both Xs are H.

Abstract: Methods and devices for treatment of damaged tissue are disclosed, including treatment of wounds by employing non-electrically powered, reduced pressure therapy devices. Maintenance and control of the sub atmospheric pressure exerted may be provided by such devices while minimizing discomfort to the user. The devices may be configured to be worn inconspicuously underneath clothing.

Abstract: Methods and devices for treatment of damaged tissue are disclosed, including treatment of wounds by employing non-electrically powered, reduced pressure therapy devices. Maintenance and control of the sub atmospheric pressure exerted may be provided by such devices while minimizing discomfort to the user. The devices may be configured to be worn inconspicuously underneath clothing.

Abstract: Devices used to drain fluid are disclosed. The devices may be configured to drain fluid from a body cavity using a vacuum pressure. The devices include a reservoir and a vacuum generating member configured to expand the reservoir and generate a vacuum pressure within the reservoir. The devices can be configured to be shipped in a collapsed state.

Abstract: Apparatus and methods for concentrating platelet-rich plasma is described herein. One variation may generally comprise a tube having a length and defining a channel within and one or more ports located at a proximal end of the tube and in fluid communication with the channel. A plunger may slidably translatable within the channel while forming a seal against an inner surface of the channel and a float may have a pre-selected density and defining a concave interface surface, wherein the float is slidably contained within the channel such that the concave interface surface is in apposition to the one or more ports.

Abstract: A device for expression and collection of breast milk includes an actuatable assembly and a breast interface. The breast interface is sized to receive a breast and form a fluid tight seal against the breast. The breast interface includes an expandable membrane disposed within at least a portion of the breast interface. The expandable membrane reversibly deforms in response to actuation of the actuatable assembly, thereby applying vacuum pressure at the breast to express milk. The expandable membrane comprises a plurality of expandable pleats which extend radially outward from a central longitudinal axis of the breast interface.

Abstract: A lactation system is disclosed. Embodiments include at least one extraction mechanism including a compression mechanism and a collection mechanism, and a controller. The compression mechanism can include a plurality of manipulable members, each operably coupled to an actuator and arrangeable circumferentially about a breast of a user such that each member can be actuated to selectively apply pressure to a region of the breast. The collection mechanism can be removably coupleable to the compression mechanism and can comprise a storage compartment to receive and store milk The controller can be operably coupleable to the actuators to cause the members to move according to a movement pattern which can be configured to stimulate the breast to induce the flow of milk from the breast and modulated based on sensor feedback. A wearable garment with an inner structure can be removably coupled to the extraction mechanism. An outer cover can be arrangeable to conceal the extraction mechanism.

Abstract: A hands-free milk extraction and collection device including a milk collection container and a housing unit. The milk collection container includes an internal cavity having a first section for receiving a nipple region of a woman's breast and having a second section for collecting milk extracted from the woman's breast. The housing unit is configured to latch onto the nipple region of the woman's breast to aid in stimulating milk flow from the breast by creating suction pressure at the nipple region. The housing unit having a shape contoured to a woman's breast and including a center opening for enclosing the milk collection container, wherein the housing unit and the enclosed milk collection container are collectively configured to fit inside a woman's bra for hands-free usage.

Abstract: Provided is a massaging device including: a housing; an adsorption unit mounted in the housing and adsorbed on the skin so as to be moved along the skin; and a cooling and heating system installed in the adsorption unit to cool or heat the adsorption unit thereby allowing cold and hot thermal energies to directly penetrate into the skin through the adsorption unit contacting the skin. Further, the cold and hot thermal energies generated in the cooling and heating system can act directly on the skin through the adsorption unit, so that the cold and hot thermal energies penetrate deeply into the skin, thereby removing the waste materials, harmful substances and fatigue substances accumulated in the skin.

Abstract: An extracorporeal-circulation blood pump device (10) includes a pump body (22) to which a catheter (16) for removing blood from a patient (100) is connected, and which houses an impeller (14) in a rotatable manner; and a drive device (24) detachably mounted to the pump body (22) and rotating the impeller (14). The pump device (10) also has a wound covering sheet (30) to be attached to the body surface (102) of the patient (100). The wound covering sheet (30) can cover both the pump body (22) and at least a location where the catheter (16) is inserted into the body.

Abstract: An implantable device for improving the pump function of the heart of a human patient by applying an external force on a first position of the heart muscle following the heart's contractions. The implantable device comprising a first pump device adapted to assist the pump function of the heart. The pump device comprises a first reservoir having a first volume and adapted to varying said first volume, a second reservoir having a second volume and adapted to varying said second volume, a fluid connection adapted to fluidly connect said first reservoir with said second reservoir, such that fluid can flow between said first reservoir and said second reservoir.